Development Of COVID-19/Influenza Combo Vaccine
29/03/2022 13:47
March 29 (Reuters) - Prestige Biopharma Ltd 950210.KS :
* PRESTIGE BIOPHARMA ENTERS MOU WITH VAXINE FOR SUPPLY OF
COVID-19
VACCINE AND CO-DEVELOPMENT OF COVID-19/INFLUENZA COMBO VACCINE
Source text for Eikon: ID:nBw5Vb2cla
Further company coverage: 950210.KS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prestige Biopharma
See all newsBrief: Prestige Biopharma Wins 2 Billion Won Order
Brief: Prestige Biopharma Receives Final Market Approval From The European Commission For Drug ‘Tuznue,’ For The Treatment Of Breast Cancer And Metastatic Gastric Cancer
Australia's Imagion Biosystems rises on MOU for cancer detection device
Brief: Prestige Biopharma And Intas Pharmaceuticals Announce Partnership To Commercialize Bevacizumab Biosimilar
Brief: Prestige Biopharma Signs Pharmaceutical Contract Manufacturing Agreement With Benevira Inc